Annual report pursuant to Section 13 and 15(d)

Document And Entity Information

Document And Entity Information - USD ($)
$ in Billions
12 Months Ended
Jun. 30, 2019
Aug. 26, 2019
Dec. 31, 2018
Document Information [Line Items]      
Entity Registrant Name BIO-TECHNE Corp    
Entity Central Index Key 0000842023    
Trading Symbol tech    
Current Fiscal Year End Date --06-30    
Entity Filer Category Large Accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer Yes    
Entity Emerging Growth Company false    
Entity Small Business false    
Entity Common Stock, Shares Outstanding (in shares)   38,063,504  
Entity Public Float     $ 5.5
Entity Shell Company false    
Document Type 10-K/A    
Document Period End Date Jun. 30, 2019    
Document Fiscal Year Focus 2019    
Document Fiscal Period Focus FY    
Amendment Flag true    
Amendment Description This Amendment No. 2 to Annual Report on Form 10-K/A (“Amendment No. 2”) amends Bio-Techne Corporation’s (the “Company”) Amendment No. 1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2019, as filed with the Securities and Exchange Commission (“SEC”) on October 9, 2019 (the “Amendment No. 1”). This Amendment No. 2 is filed solely to correct the date of the audit opinion, from October 9, 2019 to August 28, 2019, referenced in KPMG LLP’s (“KPMG”) reports included in Amendment No. 1. The August 28, 2019 date was inadvertently updated in the process of filing Amendment No. 1. Neither the error in the report contained in Amendment No. 1 nor the correction of such error in this Amendment No. 2 affect KPMG's unqualified opinion on the Company's consolidated financial statements or KPMG's unqualified opinion on internal control over financial reporting included in the original 10-K filing dated August 28, 2019 (“Original Filing”), Amendment No. 1, or this Amendment No. 2. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, this Amendment No. 2 includes a new consent of KPMG (Exhibit 23.1), new certifications from the Company's principal executive officer (Exhibit 31.1) and principal financial officer (Exhibit 31.2) and new Section 1350 certifications (Exhibit 32.1 and 32.2) dated as of the date of filing of this Amendment No. 2. This Amendment No. 2 consists solely of the preceding cover page, this explanatory note, Part II., Item 8., “Consolidated Financial Statements and Supplementary Data,” in its entirety, Item 15., “Exhibits and Financial Statement Schedules,” in its entirety, the signature page, and the new certifications from the Company’s principal executive officer and principal financial officer. Except as expressly set forth above, this Amendment No. 2 does not, and does not purport to, amend, update or restate the information in any other item of Amendment No. 1 or the Original Filing. Amendment No. 2 speaks as of the date of the Original Filing, does not reflect events that may have occurred after the date of the Original Filing and does not modify or update in any way the disclosures made in the Original Filing, except as described above. Amendment No. 2 should be read in conjunction Amendment No. 1 and with the Original Filing and with the Company’s subsequent filings with the SEC.    
Title of 12(b) Security Common Stock